Novel Triazolo(4,5-D)Pyrimidine Compounds

专利摘要:
The present invention relates to novel triazolo [4,5-d] pyrimidine compounds of formula (I), their use as medicaments, compositions containing them and methods for their preparation. <Formula I>
公开号:KR20010081054A
申请号:KR1020017006907
申请日:1999-12-02
公开日:2001-08-25
发明作者:사이몬 구일；데이비드 하던；안소니 인골；브라이언 스프링토프；폴 윌리스
申请人:다비드 에 질레스；아스트라제네카 아베；
IPC主号:

专利说明:

Novel Triazolo (4,5-D) Pyrimidine Compounds} Novel Triazolo [4,5-d] pyrimidine Compounds
[2] Platelet adhesion and aggregation is a phenomenon that initiates arterial thrombosis. The process of platelet adhesion to the endothelial surface may play an important role in the repair of damaged blood vessel walls, but its onset platelet aggregation promotes acute thrombotic occlusion of vascular beds, leading to myocardial infarction and unstable angina ( such as unstable angina, can cause high mortality. The success of intervention methods such as thrombolysis and angiogenesis, which are used to prevent or alleviate these conditions, is also damaged by platelet-mediated occlusion or reclosure.
[3] Many astringent pathways induce platelet aggregation. Whatever the initial stimulus, the final common phenomenon is the crosslinking of platelets by the binding of fibrinogen to the membrane-binding site glycoprotein IIb / IIIa (GPIIb / IIIa). The high antiplatelet efficacy of antibodies or antagonists against GPIIb / IIIa is explained by their inhibition of this final common phenomenon. However, this efficacy may also explain the problem of bleeding observed with this class of drugs. Although thrombin can cause platelet aggregation, mostly independent of other pathways, a significant amount of thrombin does not seem to exist without platelets being preactivated by other mechanisms. Thrombin inhibitors such as hirudin are very effective antithrombotic agents because they act as both antiplatelet and anticoagulants, but may also cause excessive bleeding (The TIMI 9a Investigators (1994), Circulation 90, pp. 1624-1630; The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Circulation 90, pp. 1631-1637; Neuhaus KL et. Al. (1994) Circulation 90, pp. 1638-1642).
[4] Adenosine 5'-diphosphate (ADP) has been shown to act as the main mediator of thrombosis. The pivotal role for ADP is evidenced by the fact that other agents, such as adrenaline and 5-hydroxytriptamine (5HT, serotonin), only cause aggregation in the presence of ADP. The limited antithrombotic efficacy of aspirin may reflect the fact that it releases in a thromboxane-dependent manner and subsequently blocks only one source of ADP that induces platelet adhesion (see Antiplatelet Trialists' Collaboration (1994)). , Br. Med. J. 308, pp. 81-106 and Antiplatelet Trialists' Collaboration (1994), Br. Med. J. 308, pp. 159-168). Aspirin has no effect on aggregation caused by damaged cells or other sources of ADP, such as free ADP under conditions of disrupted blood flow.
[5] ADP-induced platelet aggregation is mediated by the P _2T receptor subtype located on the platelet membrane. P _2T receptors (also known as P2Y _ADP or P2T _AC ) are primarily G-protein coupled receptors that are involved in mediating platelet aggregation / activation and have not yet been cloned. Pharmacological characteristics of this receptor are described, for example, in Humphries et al., Br. J. Pharmacology (1994), 113, 1057-1063 and Fagura et al., Br. J. Pharmacology (1998) 124, 157-164. Recently, it has been found that antagonists for this receptor provide more significant improvement than other antithrombotic agents ( J. Med. Chem. (1999) 42, 213). Therefore, there is a need to develop additional P _2T (P2Y _ADP or P2T _AC ) antagonists as antithrombotic agents.
[6] International patent application WO 9905143 describes a series of triazolo [4,5-d] pyrimidine compounds with activity as P _2T (P2Y _ADP or P2T _AC ) antagonists. In the present invention, certain compounds, which are included within the scope of international patent application WO 9905143 but are not described in detail, have surprisingly high potency with high metabolic stability and bioavailability and are therefore expected to be therapeutically effective for the continuous inhibition of aggregation in humans. It has been found that there is an advantage in dosage.
[1] The present invention relates to novel triazolo [4,5-d] pyrimidine compounds, their use as medicaments, compositions containing them and methods for their preparation.
[7] Thus, in a first aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or solvate of such salts:
[8]
[9] In the above formula,
[10] R ¹ is C _3-5 alkyl optionally substituted by one or more halogen atoms;
[11] R ² is a phenyl group optionally substituted by one or more fluorine atoms;
[12] R ³ and R ⁴ are both hydroxy;
[13] R is XOH, where X is CH ₂ , OCH ₂ CH ₂ or a bond;
[14] Provided that when X is CH ₂ or a bond, R ¹ is not propyl,
[15] If X is CH ₂ and R ¹ is CH ₂ CH ₂ CF ₃ , butyl or pentyl, then the phenyl group in R ² should be replaced by fluorine,
[16] If X is OCH ₂ CH ₂ and R ¹ is propyl, then the phenyl group in R ² must be replaced by fluorine.
[17] Alkyl groups, either alone or as part of another group, are straight and fully saturated.
[18] Suitably R ¹ is C _3-5 alkyl optionally substituted by one or more fluorine atoms. Preferably R ¹ is C _3-5 alkyl optionally substituted on the terminal carbon by three fluorine atoms. More preferably R ¹ is 3,3,3-trifluoropropyl, butyl or propyl.
[19] Suitably R ² is phenyl or phenyl substituted by one or more fluorine atoms. Preferably R ² is phenyl, 4-fluorophenyl or 3,4-difluorophenyl.
[20] Suitably R is XOH, where X is CH ₂ , OCH ₂ CH ₂ or a bond.
[21] Preferably R is CH ₂ OH or OCH ₂ CH ₂ OH.
[22] Particularly preferred compounds include the following compounds and their pharmaceutically acceptable salts or solvates, or solvates of such salts:
[23] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5-[(3,3 , 3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2 -Diol;
[24] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[( 3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane- 1,2-diol;
[25] [1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propyl Thio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol;
[26] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol;
[27] [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (4-fluorophenyl) cyclopropyl] amino]- 3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2,3-triol;
[28] [1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[( 3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy)- Cyclopentane-1,2-diol;
[29] [1S- [1α, 2α, 3β, 5β (1S ^* , 2R ^* )]]-3- (2-hydroxyethoxy) -5- [7- (2-phenylcyclopropyl) amino] -5- [ (3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2-diol;
[30] [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] cyclopentane-1,2,3-triol;
[31] [1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [5- (butylthio) -7-[(2-phenylcyclopropyl) amino] -3H-1,2, 3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol.
[32] According to the invention, (a) reacting a compound of formula (II) with a compound of formula (III) or, if X is a bond, (b) hydroxylating a compound of formula (IV), both (a) and (b) And optionally optionally converting one or more functional groups into additional functional groups, removing a protecting group, or forming a pharmaceutically acceptable salt or solvate or solvate of such salts in any order. Provided is a process for preparing a compound of formula (I) characterized by the following:
[33]
[34]
[35]
[36] R, R ¹ , R ³ and R ⁴ in Formula II are as defined in Formula I, or a protected derivative thereof, R ³ and R ⁴ together form a 5-membered ring, or R is CH ₂ CH ₂ OR 'wherein R' is C _1-6 alkyl or benzyl, L is a leaving group such as halogen or SR,
[37] R ² in Formula III is the same as defined in Formula I, or a protected derivative thereof,
[38] R ¹ in Formula IV is as defined in Formula I, R ⁸ is H or CH ₂ CH ₂ OP ³ , wherein P ³ is H or a protecting group, or R ⁸ is CH ₂ COOR ', wherein R 'Is C _1-6 alkyl or benzyl and Z is NH ₂ or Where R ² is as defined in formula (I).
[39] The compound of formula (II) can be reacted with an amine of formula (III) at ambient or elevated temperature in an inert solvent such as dichloromethane in the presence of a base such as a tertiary organic amine. Other suitable bases include inorganic bases such as potassium carbonate.
[40] Hydroxy groups R ³ and R ⁴ may be protected as groups OP ¹ and OP ² , wherein P ¹ and P ² are protecting groups. Examples of suitable protecting groups in the compounds of formula II are C _1-6 alkyl (preferably methyl), benzyl, (C _1-6 alkyl) ₃ Si (preferably t-butyldimethylsilyl), and C such as acetyl (O) C _1-6 alkyl group. Preferably the two groups P ¹ and P ² together with the atoms to which they are attached form an alkylidene ring, such as a methylidene or isopropylidene ring. Alternatively, P ¹ and P ² may also form an alkoxymethylidene ring such as ethoxymethylidene.
[41] Protective groups can be added and removed using known reaction conditions. The use of protected groups is described in 'Protective Groups in Organic Chemistry', edited by JWF McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2ndedition, TW Greene & PGM Wutz, Wiley-Interscience (1991). It is described in detail in.
[42] The ester protecting group is, for example, an alkali such as metal hydroxide, preferably sodium hydroxide or lithium hydroxide, in a solvent such as aqueous ethanol or aqueous tetrahydrofuran at a temperature of 10 ° C. to 100 ° C., preferably approximately room temperature. By basic hydrolysis with metal hydroxides, or quaternary ammonium hydroxides, or by acid hydrolysis with inorganic acids, such as HCl, or strong organic acids, such as trichloroacetic acid, in a solvent such as aqueous 1,4-dioxane Can be removed. Trialkylsilyl protecting groups can be removed using, for example, a fluoride ion source, for example tetra-n-butylammonium fluoride or hydrogen fluoride. If one or both of P ¹ and P ² are C _1-6 alkyl, deprotection can be achieved using borontribromide. Benzyl groups can be removed by hydrogenolysis using a transition metal catalyst, for example palladium on charcoal, in a solvent such as acetic acid at a pressure of 1 to 5 bar under hydrogen atmosphere.
[43] The compound of formula (II) is prepared by reacting the compound of formula (V) with a metal nitrite, for example alkali metal nitrite, especially sodium nitric acid in dilute aqueous acid, such as 2M HCl, or C in an inert solvent at a temperature of about -20 to about 100 ° C. It can be prepared by diazotizing with _{1-6 alkylnitrite} :
[44]
[45] Wherein R ¹ is as defined in formula (I), and R is as defined in formula (I), or a protected derivative thereof, or is OCH ₂ CO ₂ R ', wherein R' is C _1-6 alkyl or benzyl And L is as defined above and R ³ and R ⁴ are as defined in formula (I) or a protected derivative thereof or R ³ and R ⁴ together form a 5-membered ring. Preferred conditions here are to use isoamylnitrite in acetonitrile at about 80 ° C.
[46] Compounds of formula (V) wherein R is CH ₂ OH, R ³ and R ⁴ are hydroxyl or a protected derivative thereof and L is as defined above can be prepared by reducing the compound of formula (VI):
[47]
[48] Wherein R ¹ , L, P ¹ and P ² are as defined above.
[49] Reduction of the nitro group can be effected, for example, using hydrogenation with a transition metal catalyst, for example palladium on charcoal, at about room temperature under hydrogen atmosphere, preferably at a pressure of 1 to 5 atmospheres, in a solvent such as ethanol, It can be performed with iron in an acidic solvent such as acetic acid at a temperature of about 100 ° C.
[50] Reduction of the lactam may be carried out using complex metal hydrides such as lithium aluminum hydride in a solvent such as ether, or preferably sodium borohydride in a suitable solvent such as methanol.
[51] Compounds of formula (VI) may be selected from compounds of formula (VII) in bases such as C _1-6 -alkyl-M or MH in an inert solvent such as tetrahydrofuran at a temperature of about -10 to about 100 ° C, where M is a metal ion. For example by reacting with a compound of formula VIII in the presence of n-butyllithium:
[52]
[53]
[54] Wherein L and R ¹ are as defined above, L ¹ is a leaving group, for example a halogen atom, where L and L ¹ are preferably the same and P ¹ and P ² are as defined above same. Preferably, sodium hydride is used in tetrahydrofuran at room temperature.
[55] One or more functional groups can be converted to additional functional groups using standard chemical methods. Compounds wherein X is a bond are treated with a base, followed by LY (where L is a leaving group and Y is (CH ₂ ) ₂ OH or a protected group thereof, or Y is CH ₂ COOR ', wherein R' is C _1-6 alkyl or benzyl) to convert to compounds in which X is O (CH ₂ ) ₂ . Compounds in which R is CH ₂ CH ₂ OR 'can be converted to compounds in which R is O (CH ₂ ) ₂ OH, for example by reduction with DIBAL-H ™. A group SR ^1, for example, Oxone (oxone ™), or the oxidation reaction of sulfur with mCBPA was then compound R ^{1 '-SM} (R ^{1, where'} is a different R ¹ groups, M is a metal such as sodium) with Can be interchanged by processing. Alternatively, the product of sulfur oxidation is treated with MSH (where M is a metal such as sodium), followed by base and R ^{1 ′} X where R ^{1 ′} is a different R ¹ group and X is leaving Group). Suitable bases include N, N-diisopropylethylamine.
[56] R, R ¹ , R ³ and R ⁴ are as defined in formula (I) or a protected derivative thereof, or R ³ and R ⁴ together form a bond in a 5-membered ring, or R is OCH ₂ CO ₂ R ' , Wherein R 'is C _1-6 alkyl or benzyl and L is a leaving group such as halogen by treating the compound of formula II with a diazotizing agent, preferably isoamylnitrite and carbon tetrabromide in the presence of a halogenating agent R, R ¹ , R ³ and R ⁴ are as defined above and L can be converted to a compound of formula II wherein NH ₂ .
[57] Compounds of formula II wherein R, R ¹ , R ³ and R ⁴ are as defined above and L is NH ₂ are those wherein R, R ¹ , R ³ and R ⁴ are as defined above and L is a leaving group such as halogen Compounds of formula II can be prepared by treatment with ammonia in a solvent such as methanol.
[58] Compounds of formula V can also be prepared by treating a compound of formula XI with a compound of formula VII as defined above, followed by reduction of the nitro group:
[59]
[60] Wherein R, R ³ and R ⁴ are as defined in formula (I) or a protected derivative thereof, or R is OCH ₂ CO ₂ R ', wherein R' is C _1-6 alkyl or benzyl, or R ³ and R ⁴ together form a bond in a 5-membered ring. The reaction is carried out in an inert solvent such as dichloromethane or 1,4-dioxane in the presence of a non-nucleophilic base such as N, N-diisopropylamine at a temperature of from about -20 ° C to about 150 ° C, preferably at ambient temperature. do.
[61] Compounds of formula II wherein R is as defined in formula I, R ³ and R ⁴ together form a 5-membered ring, and L is SR ¹ or a protected derivative thereof, reacting a compound of formula XII with a compound of formula XIII It can be prepared by:
[62]
[63]
[64] Wherein R ¹ group is as defined for formula (I) and R ⁷ is H or a protected derivative thereof. The reaction can be carried out in the presence of a suitable transition metal complex, preferably tetrakistriphenylphosphine palladium (O).
[65] Compounds of formula (XII) can be prepared by reacting a compound of formula (XIV) with compound R ¹ X (wherein R ¹ is as defined in formula (I) and X is a leaving group such as halo) and then ring closure:
[66]
[67] Compounds of formula (XI) wherein R is OH or a protected form thereof and R ³ and R ⁴ are as defined in formula (I) or a protected derivative thereof, use a palladium catalyst for compounds of formula (XIII) wherein R ⁷ is H or a protecting group It can also be prepared by treatment with a bisester of imidodicarbamic acid, followed by hydroxylation of the double bond and optionally deprotection of nitrogen. Preferably imidodicarboxylic acid bis- (1,1-dimethylethyl) ester and tetrakistriphenylphosphine palladium (O) are used, followed by osmium tetraoxide followed by deprotection with hydrochloric acid in methanol.
[68] Compounds of formula (XI) wherein R is OCH ₂ CO ₂ R 'wherein R' is C _1-6 alkyl, and R ³ and R ⁴ together form a 5-membered ring, R ⁷ is H or a protecting group Phosphorus compounds of formula (XIII) can be formed by treating with azide in the presence of a palladium catalyst and then reducing the azide and alkylating the alcohol as described above.
[69] Compounds of formula (XI) wherein R is OCH ₂ CH ₂ OH and R ³ and R ⁴ are as defined in formula (I) or a protected derivative thereof are compounds of formula (XI) wherein R is OH and R ³ and R ⁴ are as defined in formula (I) or Can be prepared by protecting nitrogen from a compound of formula XI which is a derivative, and alkylating the alcohol using a 2-halo-acetic acid ester, followed by reducing the ester and deprotecting the nitrogen. In this case nitrogen is protected with carbobenzyloxy derivatives using benzylchloroformate, followed by alkylation of the alcohols with ethylbromoacetate and potassium t-butoxide, followed by lithium borohydride in tetrahydrofuran. Preference is given to reducing the ester and hydrogenating in the presence of palladium on carbon to deprotect the nitrogen. It is also preferred if the alcohols R ³ and R ⁴ are protected with an isopropylidene ring.
[70] Amines of formula III are described in J. Chem. Nishiyama et al., Bull. Chem. Soc., Jpn., 1995, 68, 1247; P. Newman, Optical Resolution Procedures for Chemical Compounds, Vol. 1, Amines and Related Compounds; Optical Resolution and Information Center: Manhattan College, Riverdale, NY, 1978, p. 120, J. Vallgarda et al., J. Chem. Soc. Perkin I, 1994, 461, or International Patent Application No. WO 9905143.
[71] All novel intermediates are a further object of the present invention.
[72] Salts of the compounds of formula (I) may comprise free acid, or salts thereof, or free bases or salts or derivatives thereof, with one or more equivalents of a suitable base (e.g. ammonium hydroxide, or an alkali metal, optionally substituted by C _1-6 -alkyl) Alkaline earth metal hydroxides) or acids (for example hydrochloric acid (especially HCl), sulfuric acid, oxalic acid or phosphoric acid). The reaction can be carried out in a solvent or medium in which the salt does not dissolve, or in a solvent in which the salt is soluble, such as water, ethanol, tetrahydrofuran or diethyl ether, which can be removed by removal or lyophilization in vacuo. The reaction may also be a metathesis process or may be carried out on an ion exchange resin. Physiologically acceptable non-toxic salts are preferred, but other salts may be useful, for example when separating or purifying the product.
[73] Compounds of the invention act as P _2T (P2Y _ADP or P2T _AC ) receptor antagonists. Thus, the compounds are useful in therapeutic methods, including combination therapy, in particular they are used for the following indications: inhibitors of platelet activation, aggregation and degranulation, accelerators of platelet separation, antithrombicides, or unstable angina, Primary arterial thrombotic complications of atherosclerosis, transient ischemic attack, peripheral vascular disease, myocardial infarction with or without thrombolytics, angiogenesis including coronary angiogenesis (PTCA), endovascular resection, stent politics such as thrombotic or embolic stroke ( thrombotic complications of surgery or mechanical damage, such as arterial complications caused by intervention in atherosclerotic diseases, such as stent placement, graft surgery of coronary and other blood vessels, tissue rescue following accidents or surgical trauma, skin and muscle fragments Reconstructive surgery, including disseminated intravascular coagulopathy, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome Group, thrombotic complications of sepsis, adult respiratory distress syndrome, anti-phospholipid syndrome, heparin-induced thrombocytopenia and conditions with diffuse thrombotic / platelet consuming components such as preeclampsia / eclampsia, or deep vein thrombosis, venous Treating or preventing hematologic conditions such as venous thrombosis, such as embolic diseases, myeloproliferative diseases, including thrombocytopenia, sickle cell disease; Or in vitro mechanically induced platelets such as those used for mechanically induced platelet activation in vivo, such as cardiopulmonary circuitry and extracorporeal membrane oxidation (prevention of microthromboembolism), for the preservation of blood products, for example platelet concentrates. Thrombosis, conditions such as migraine, Raynaud's phenomenon, secondary to vascular damage / inflammation, such as activation, or short-circuit occlusion, vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease, and organ transplant rejection as in renal dialysis and plasma Raynaud's phenomenon, conditions in which platelets may be responsible for the process of the original inflammatory disease in the vessel wall, such as atherosclerotic plaque formation / progression, stenosis / restenosis, and platelet and platelet-induced factors are involved in the process of immunological disease Prevention of other inflammatory conditions, such as asthma. Indications also include treatment of CNS disease and prevention of tumor growth and spread.
[74] According to the invention, there is also provided the use of a compound according to the invention as an active ingredient in the manufacture of a medicament for use in the treatment or prevention of the diseases mentioned above. In particular, the compounds of the present invention are useful for the treatment of myocardial infarction, thrombotic stroke, transient ischemic attacks, peripheral vascular diseases and stable and unstable angina, especially unstable angina. The present invention also provides a method for treating or preventing such a disease by administering a therapeutically effective amount of a compound according to the invention to a person suffering from or susceptible to the disease.
[75] The compound may be administered topically in the form of solutions, suspensions, HFA aerosols and dry powder formulations, for example in the lungs and / or airways, or systemically, for example in the form of tablets, pills, capsules, syrups, powders or granules. Orally, parenterally in the form of sterile parenteral solutions or suspensions, subcutaneously, rectally in the form of suppositories, or percutaneously.
[76] The compounds of the invention can be administered on their own or as pharmaceutical compositions containing the compounds of the invention in combination with pharmaceutically acceptable diluents, adjuvants and / or carriers. Particularly preferred are compositions that do not contain substances that can cause side effects such as allergic reactions.
[77] Dry powder formulations and pressurized HFA aerosols of the compounds of this invention may be administered by oral or nasal inhalation. In case of inhalation, the compound is preferably finely ground. The compounds of the present invention can also be administered using a dry powder inhaler. The inhaler may be a single or multiple dose inhaler or may be a dry powder inhaler operated by breathing.
[78] One available method is to mix the finely ground compound with a carrier material, for example mono-, di- or polysaccharides, sugar alcohols or another polyol. Suitable carriers include sugars and starches. Alternatively, the finely divided compound may be coated with another material. The powder mixture may also be dispensed such that each of the hard gelatin capsules contains the desired dose of the active compound.
[79] Another available method may be to prepare a finely ground powder into spheres that break down during the inhalation process. This spherical powder can be filled into a multi-dose inhaler, for example, a drug reservoir of an inhaler known as Turbuhaler ™, in which the dosage unit weighs the desired dose and then inhales into the patient. This system is used to deliver an active compound to a patient with or without a carrier material.
[80] Pharmaceutical compositions containing a compound of the present invention may conveniently be used in tablets, pills, capsules, syrups, powders or granules for oral administration; Sterile parenteral or subcutaneous solutions, suspensions for parenteral administration or suppositories for rectal administration.
[81] In the case of oral administration, the active compound is an adjuvant or carrier, for example a binder such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch or amylopectin, a binder such as cellulose derivatives, gelatin or polyvinylpyrrolidone And may be mixed with lubricants such as magnesium stearate, calcium stearate, polyethylene glycol, wax, paraffin and the like and then compressed into tablets. If coated tablets are required, the core prepared as described above may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatin, talc, titanium dioxide and the like. Alternatively, the tablet may be coated with a suitable polymer dissolved in an easily volatile organic or aqueous solvent.
[82] In the preparation of the soft gelatin capsules, the compound may be mixed with, for example, vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the excipients mentioned in the case of tablets above, for example, lactose, saccharose, sorbitol, mannitol, starch, cellulose derivatives or compounds using gelatin. Liquid or semisolid formulations of the drug may also be filled into hard gelatin capsules.
[83] Liquid preparations for oral application may be in the form of solutions containing syrups or suspensions, for example compounds, the remainder being sugars and mixtures of ethanol, water, glycerol and propylene glycol. Optionally, such liquid preparations may also contain carboxymethylcellulose as colorants, fragrances, saccharines and thickening agents, or other excipients known in the art.
[84] The invention is illustrated by the following non-limiting examples.
[85] In the examples, NMR spectra were measured on a Varian Unity Inova 300 or 400 spectrometer and MS spectra were measured as follows: EI spectra were VG 70-250S or Finigangan Matt Incos-XL (Finnigan Mat Incos-XL spectrometer, FAB spectra were measured on the VG70-250SEQ spectrometer, and ESI and APCI spectra were measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer. Preparative HPLC separations were generally performed using Novapak ™, Bondapak ™ or Hypersil ™ columns filled with BDSC-18 reversed phase silica. Flash chromatography (denoted as (SiO ₂ ) in the examples) was performed using Fisher Matrix silica 35-70 μm. Examples showing the presence of rotamers in the proton NMR spectrum only exemplify the chemical shifts of the main isomers.
[86] Example 1
[87] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H-1, 2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[88] a) [3aS- [1 (E), 3aα, 6α, 7aβ]]-1- [3- (4-fluorophenyl) -1-oxo-2-propenyl] -hexahydro-8,8-dimethyl -3H-3a, 6-methano-2,1-benzisothiazole-2,2-dioxide
[89] A mixture of 3- (4-fluorophenyl) -2-propenoic acid (3.0 g) and thionylchloride (5.0 mL) was stirred at 70 ° C. for 1 hour, and then the reaction mixture was concentrated under reduced pressure. The residue was azeotroduced twice with dichloromethane and then dissolved in toluene (10 mL). To a suspension of sodium hydride (60% dispersion in oil; 0.99 g) in toluene (40 mL) [3aS- (3aα, 6α, 7aβ)]-hexahydro-8,8-dimethyl-3H in toluene (40 mL) A solution of -3a, 6-methano-2,1-benzisothiazole-2,2-dioxide (3.89 g) was added and the mixture was stirred for 30 minutes. Thereafter, the above-mentioned solution was added to the reaction mixture, and the resulting suspension was stirred for 16 hours. Water (200 mL) was added to collect the organic phase, and the aqueous phase was extracted with dichloromethane (3 × 100 mL). The combined organic phases were dried and concentrated. Recrystallization (ethanol) afforded the subtitle compound (5.92 g) as colorless needles.
[90] MS (APCI) 364 (M + H ⁺ , 100%)
[91] b) [3aS- [1 (1S ^* , 2S ^* ), 3aα, 6α, 7aβ]]-1-[[2- (4-fluorophenyl) cyclopropyl] carbonyl] -hexahydro-8,8-dimethyl-3H-3a, 6-methano-2, 1-benzisothiazole-2,2-dioxide
[92] A solution of diazomethane (2.9 g) in ether (150 mL) (prepared as described in Vogel's Textbook of Practical Organic Chemistry, Fifth Edition, Longman Scientific and Technical, p432) in step of dichloromethane (350 mL) To a solution of the product of a) (5.90 g) and palladium (II) acetate (18 mg) was added at 0 ° C. and the reaction mixture was stirred at 0 ° C. for 5 hours. Acetic acid (5 mL) was added, then the reaction mixture was washed with saturated sodium bicarbonate solution (200 mL) and the organic phase was filtered through a plug of silica. After concentration in vacuo, the residue was recrystallized (ethanol) to give the title compound (3.81 g) as a colorless needle.
[93] MS (APCI) 378 (M + H ⁺ , 100%)
[94] c) (1R-trans) -2- (4-fluorophenyl) -cyclopropanecarboxylic acid
[95] A suspension of the product of step b) (3.74 g) and lithium hydroxide monohydrate (4.11 g) in tetrahydrofuran (100 mL) / water (3 mL) was stirred at 50 ° C. for 24 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in water (100 mL) and acidified with 2N HCl and extracted with dichloromethane (3 × 75 mL). The organic phase was dried and concentrated. Purification (SiO ₂ , isohexane: diethylether 2: 1 as eluent) gave the title compound (1.78 g) as a colorless solid.
[96] MS (APCI) 179 (MH ⁺ , 100%)
[97] d) (1R-trans) -2- (4-fluorophenyl) cyclopropanamine, [R- (R ^* , R ^* )]-2,3-dihydroxybutanedioate (1: 1)
[98] To a solution of step c) (1.78 g) and triethylamine (2.7 mL) in acetone / water (10: 1, 23 mL) was added ethylchloroformate (2.0 mL) at 0 ° C. over 5 min. . After the solution was held at 0 ° C. for 30 minutes, sodium azide (1.52 g) in water (6 mL) was added. After 1 h more water (350 mL) was added and the reaction mixture was extracted with toluene (3 × 100 mL). The combined organic extracts were dried and then heated under reflux for 2 hours behind a blast screen. After cooling the solution, 6 N HCl (50 mL) was added and the mixture was heated at reflux for 3 h. Water (150 mL) was added and the aqueous phase was made basic with 2N NaOH (aq) and then extracted with dichloromethane (3 × 100 mL). The organic phase was dried and concentrated. The amine was dissolved in ethanol (5 mL) and a solution of L-tartaric acid (1.48 g) in ethanol (20 mL) was added. After 20 minutes, the solids were collected to give the subtitle compound (1.12 g) as colorless needles.
[99] NMR δH (d ₆ -DMSO) 1.07-1.39 (1H, m), 1.22-1.29 (1H, m), 2.16-2.23 (1H, m), 2.64-2.70 (1H, m), 3.95 (2H, s) , 7.06-7.19 (4H, m)
[100] e) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4,5- d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol
[101] N, N-diisopropylethylamine (1.29 g) was added to [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-chloro-5- (propylthio) -3H in dichloromethane (25 mL). -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol (international To a solution of (1.0 g) and the product of step d) (0.75 g) as described in patent application WO 9703084. The reaction mixture was stirred at room temperature for 3 hours, then washed with water, dried and evaporated. The residue was purified (SiO ₂ , ethyl acetate: isohexane 1: 1 as eluent) to give the title compound (1.25 g).
[102] MS (APCI) 515 (M + H ⁺ , 100%)
[103] f) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol
[104] 3-chloroperoxybenzoic acid (70%, 1.8 g) was added to a suspension of the product of step e) (1.25 g) in ethanol (25 mL) and the resulting solution was stirred at rt for 2 h. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate (500 mL), washed with 10% aqueous sodium metabisulfite solution (2 x 100 mL) and 10% aqueous sodium bicarbonate solution (2 x 100 mL), dried and concentrated. Subtitled compound (1.4 g) was obtained.
[105] MS (APCI) 547 (M + H ⁺ , 100%)
[106] g) [[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H-1, 2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol
[107] Sodium hydrosulfide hydrate (1.4 g) was added to a solution of the product of step f) (1.4 g) in dimethylsulfoxide (20 mL) and the solution was stirred at rt for 1.5 h. Brine (150 mL) was added and the mixture was acidified with acetic acid and then extracted with ethyl acetate (3 × 100 mL). The organic phase was dried and concentrated to azeotrope the residue with toluene (3 × 100 mL). The residue was dissolved in N, N-dimethylformamide (20 mL), and then N, N-diisopropylethylamine (0.33 g) and 3,3,3-trifluoropropylbromide (0.48 g) were added. It was. After stirring for 30 min at 50 ° C., the reaction mixture was diluted with ethyl acetate (100 mL), then washed with aqueous brine (3 × 100 mL), dried and concentrated, and the residue purified (SiO ₂ , solvent). Isohexane: ethyl acetate 1: 1) was used as a starting material to obtain a small title compound (1.4 g).
[108] MS (APCI) 569 (M + H ⁺ , 100%)
[109] h) [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H-1, 2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[110] A solution of the product of step g) (1.4 g) in trifluoroacetic acid (10 mL) and water (2 mL) was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (400 mL), then washed with sodium bicarbonate solution (400 mL), dried and evaporated. The residue was purified (SiO ₂ , methanol: chloroform 3:47 as eluent) to afford the title compound (0.44 g).
[111] MS (APCI) 529 (M + H ⁺ , 100%)
[112] NMR δH (d ₆ -DMSO) 9.42 (1H, d), 7.27-7.22 (2H, m), 7.14-7.08 (2H, m), 5.01-4.95 (2H, m), 4.73-4.70 (2H, m) , 4.44-4.41 (1H, m), 3.87-3.84 (1H, m), 3.50-3.45 (2H, m), 3.26-3.13 (3H, m), 2.60-2.55 (1H, m), 2.28-2.20 ( 2H, m), 2.10-2.06 (1H, m), 1.90-1.80 (1H, m), 1.49-1.46 (1H, m), 1.33-1.30 (1H, m)
[113] Example 2
[114] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[115] a) [3aS- [1 (E), 3aα, 6α, 7aβ]]-1- [3- (3,4-difluorophenyl) -1-oxo-2-propenyl] -hexahydro-8, 8-dimethyl-3H-3a, 6-methano-2,1-benzisothiazole-2,2-dioxide
[116] A subtitle compound was prepared according to the method of step a) of Example 1 using 3- (3,4-difluorophenyl) -2-propenoic acid.
[117] MS (APCI) 382 (M + H ⁺ , 100%)
[118] b) [3aS- [1 (1S ^* , 2S ^* ), 3aα, 6α, 7aβ]]-1-[[2- (3,4-difluorophenyl) cyclopropyl] carbonyl] -hexahydro-8,8-dimethyl-3H-3a, 6-methano -2,1-benzisothiazole-2,2-dioxide
[119] A subtitle compound was prepared according to the method of Example b) of Example 1 using the product of step a).
[120] MS (APCI) 396 (M + H ⁺ , 100%)
[121] c) (1R-trans) -2- (3,4-difluorophenyl) -cyclopropanecarboxylic acid
[122] A subtitle compound was prepared according to the method of Example c) of Example 1 using the product of step b).
[123] NMR δ H (CDCl ₃ ) 7.06 (1H, dt, J = 10.0, J = 8.5 Hz), 6.93-6.80 (2H, m), 2.58-2.52 (1H, m), 1.88-1.82 (1H, m), 1.66 (1H, dt, J = 9.2, J = 5.2 Hz), 1.34 (1H, ddd, J = 8.5, J = 6.5, J = 4.8 Hz)
[124] d) (1R-trans) -2- (3,4-difluorophenyl) cyclopropanamine, [R- (R ^* , R ^* )]-2,3-dihydroxybutanedioate (1: 1)
[125] The subtitle compound was prepared according to the method of step d) of Example 1 using the product of step c).
[126] MS (APCI) 170 (M + H ⁺ , 100%)
[127] e) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol
[128] Isoamylnitrite (5.1 mL) was dissolved in [3aR- (3aα, 4α, 6α, 6aα)]-6-[[5-amino-6-chloro-2-[(3,3,3) in acetonitrile (1000 mL). 3-trifluoropropyl) thio] -4-pyrimidinyl] -amino] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol (International patent application WO (8.1 g) was added and the solution was heated at 70 ° C. for 1 hour. The cooled reaction mixture was concentrated and purified (SiO ₂ , dichloromethane: ethylacetate 4: 1) as eluent to afford an intermediate, which was subjected to the method of step e) of example 1 using the product of step d). To the subtitle compound.
[129] MS (APCI) 587 (M + H ⁺ , 100%)
[130] f) [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[131] The title compound was prepared according to the method of step h) of Example 1 using the product of step e).
[132] MS (APCI) 547 (M + H ⁺ , 100%)
[133] NMR δH (d ₆ -DMSO) 9.43 (1H, d), 7.35-7.28 (2H, m), 7.14-7.02 (1H, m), 5.01-4.96 (2H, m), 4.72-4.69 (2H, m) , 4.42 (1H, q), 3.87-3.84 (1H, m), 3.50-3.44 (2H, m), 3.25-3.12 (3H, m), 2.58-2.50 (2H, m), 2.28-2.21 (3H, m), 1.85-1.80 (1H, m), 1.52-1.50 (1H, m), 1.39-1.37 (1H, m)
[134] Example 3
[135] [1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7- [2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4, 5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[136] a) (1R-cis) -bis (1,1-dimethylethyl) -4-hydroxy-2-cyclopentenylimidodicarbonate
[137] To a suspension of ether washed sodium hydride (60% dispersion in oil; 0.31 g) in tetrahydrofuran (30 mL) was added imidodicarboxylic acid bis- (1,1-dimethylethyl) ester (1.84 g). The mixture was stirred at 40 ° C. for 1 hour. The mixture was then added (1S-cis) -4-acetoxy-2-cyclopenten-l-ol (0.5 g) and tetrakis (triphenylphosphine) palladium (O) (0.18 g) at ambient temperature. . The reaction mixture was stirred for 24 hours and then purified (SiO ₂ , ethyl acetate: hexane 1: 9 as eluent) to give the title compound (0.90 g) as a colorless solid.
[138] NMR δH (d ₆ -DMSO) 1.43 (18H, s), 1.61 (1H, ddd, J = 12.3, 7.7, 6.4 Hz), 2.54 (1H, dt, J = 12.6, 7.4 Hz), 4.51-4.57 (1H , m), 4.86 (1H, tq, J = 8.0, 1.8 Hz), 4.91 (1H, d, J = 5.4 Hz), 5.71-5.77 (2H, m)
[139] b) [1R- (1α, 2β, 3β, 4α)]-2,3,4-trihydroxy-cyclopentenylimidodicarboxylic acid bis (1,1-dimethylethyl) ester
[140] To a solution of the product of step a) (17.1 g) in tetrahydrofuran (500 mL) / water (50 mL) was added N-methylmorpholine-N-oxide (9.4 g), followed by osmium tetroxide (10 mL , 2.5% solution in t-butanol) was added. The mixture was stirred at rt for 4 days and then treated with sodium hydrosulfite (6.0 g). The suspension was filtered through celite and the product was purified (SiO ₂ , ethyl acetate: hexane 1: 1 as eluent) to give the title compound (19.1 g).
[141] NMR δH (d ₆ -DMSO) 1.44 (18H, s), 1.46-1.60 (1H, m), 1.97-2.05 (1H, m), 3.55-3.58 (1H, m), 3.66-3.73 (1H, m) , 4.11-4.21 (2H, m), 4.54 (1H, d, J = 4.8 Hz), 4.56 (1H, d, J = 5.9 Hz), 4.82 (1H, d, J = 4.6 Hz)
[142] c) [3aR- (3aα, 4α, 6α, 6aα)]-6-amino-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-ol hydrochloride
[143] The product of step b) (17.4 g) in 6 M HCl (100 mL) / methanol (500 mL) was stirred for 18 h. The mixture was evaporated and then azeotropic with toluene (4 x 200 mL) to give a colorless powder (8.7 g). This solid was suspended in acetone (250 mL) containing 2,2-dimethoxypropane (25 mL) and cHCl (0.2 mL) and then heated under reflux for 2 hours. The mixture was cooled, evaporated and then azeotropic with toluene (3 × 200 mL). The residue was dissolved in 20% aqueous acetic acid and stirred for 2 hours. The mixture was evaporated and then azeotropic with toluene (4 × 200 mL) to give the subtitle compound (10.1 g).
[144] MS (APCI) 174 (M + H ⁺ , 100%)
[145] d) [3aR- (3aα, 4α, 6α, 6aα)]-6-[[6-chloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] amino] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[146] The solution of step c) (10.0 g) and N, N-diisopropylethylamine (35 mL) in tetrahydrofuran (600 mL) was stirred for 1 h. The mixture was filtered and the solution was taken over 4 hours in 4,6-dichloro-5-nitro-2- (propylthio) -pyrimidine in tetrahydrofuran (1000 mL) (as described in International Patent Application WO 9703084). (25.6 g) and further stirred for a further 2 hours. The volume of solvent was reduced in vacuo and ethylacetate was added (1000 mL). The mixture was washed with water, the organic layer was dried and evaporated and purified (SiO ₂ , isohexane-ethylacetate as eluent) to give the title compound (14.2 g).
[147] MS (APCI) 405 (M + H ⁺ , 100%)
[148] e) [3aR- (3aα, 4α, 6α, 6aα)]-6-[[5-amino-6-chloro-2- (propylthio) -pyrimidin-4-yl] amino] -tetrahydro-2, 2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[149] Iron powder (3.0 g) was added to a stirred solution of the product of step d) (2.7 g) in acetic acid (100 mL). The reaction mixture was stirred at room temperature for 2 hours, the volume was concentrated in half, diluted with ethyl acetate and washed with water. The organic phase was dried and concentrated to give the subtitle compound (2.0 g).
[150] MS (APCI) 375 (M + H ⁺ , 100%)
[151] f) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] -pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[152] Isoamylnitrite (1.1 mL) was added to a solution of the product of step e) (2.0 g) in acetonitrile (100 mL) and the solution was heated at 70 ° C. for 1 h. The cooled reaction mixture was concentrated and purified (SiO ₂ , ethyl acetate: isohexane 1: 3 as eluent) to give the title compound (1.9 g).
[153] MS (APCI) 386 (M + H ⁺ , 100%)
[154] g) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] -pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[155] The product of step f) (13.2 g) in tetrahydrofuran (200 mL) containing 0.88 ammonia (5 mL) was stirred for 2 h, then concentrated to dryness and the residue partitioned between water and ethyl acetate. The organic phase was dried and then concentrated to give the subtitle compound (12.5 g).
[156] MS (APCI) 367 (M + H ⁺ , 100%)
[157] h) [3aR- (3aα, 4α, 6α, 6aα)]-[[6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrid Midin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol] oxy] acetic acid methyl ester
[158] To a solution of the product of step g) (0.50 g) in tetrahydrofuran (25 mL) at 0 ° C. was added butyllithium (2.5 N in hexane, 0.62 mL). After 20 minutes, the suspension is a solution of trifluoromethanesulfonyloxy-acetic acid methylester (0.34 g) (prepared according to the method of Biton, Tetrahedron, 1995, 51, 10513) in tetrahydrofuran (10 mL). Treated with. The resulting solution was allowed to warm to room temperature, then concentrated and purified (SiO ₂ , ethyl acetate: hexane 4: 6 as eluent) to give the subtitle compound (0.25 g).
[159] MS (APCI) 439 (M + H ⁺ , 100%)
[160] i) [3aR- (3aα, 4α, 6α, 6aα)]-[[6- [7-bromo-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] Pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol] oxy] acetic acid methyl ester
[161] The product of step h) (1.1 g) and isoamylnitrite (2.4 mL) in bromoform (30 mL) were heated at 80 ° C. for 30 minutes. The cooled reaction mixture was purified (SiO ₂ , ethyl acetate: isohexane 1: 4 as eluent) to give a small title compound (0.44 g).
[162] MS (APCI) 502/4 (M + H ⁺ ), 504 (100%)
[163] j) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-[[6- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-ol] oxy] acetic acid methyl ester
[164] To a mixture of the product of step i) (0.80 g) and the product of step d) of Example 2 (0.61 g) in dichloromethane (25 mL) was added N, N-diisopropylethylamine (0.85 mL). The resulting solution was stirred at rt for 16 h, then concentrated in vacuo and purified (SiO ₂ , isohexane: ethylacetate 3: 1 as eluent) to give a small title compound (0.77 g) as a colorless foam.
[165] MS (APCI) 591 (M + H ⁺ , 100%)
[166] k) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6-[[7- [2- (3,4-difluorophenyl) cyclopropyl] amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-yl] oxy] -ethanol
[167] DIBAL-H ™ (1.0 M solution in hexane, 5.15 mL) was added to an ice cold solution of the product of step j) (0.76 g) in tetrahydrofuran (1 mL) and the solution was stirred at this temperature for 2 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate (75 mL). A saturated aqueous solution of sodium potassium tartrate (75 mL) was added and the mixture was stirred vigorously for 16 hours. The organic layer was collected and the aqueous layer was reextracted with ethyl acetate (2 × 50 mL). The combined organic layers were dried and concentrated and the residue was purified (SiO ₂ , isohexane: ethylacetate 1: 1 as eluent) to give the title compound (0.63 g).
[168] MS (APCI) 563 (M + H ⁺ , 100%)
[169] l) [1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [7- (2- (3,4-difluorophenyl) cyclopropylamino) -5- (propylthio) -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[170] The title compound was prepared according to the method of step h) of Example 1 using the product of step k).
[171] MS (APCI) 523 (M + H ⁺ , 100%)
[172] NMR δ H (d ₆ -DMSO) 8.95 (1H, d, J = 3.3 Hz), 7.39-7.21 (2H, m), 7.10-7.00 (1H, m), 5.12 (1H, d, J = 6.4 Hz), 5.50 (1H, d, J = 3.6 Hz), 4.96 (1H, q, J = 9.0 Hz), 4.62-4.54 (2H, m), 3.95 (1H, br s), 3.79-3.73 (1H, m), 3.55-3.47 (4H, m), 3.20-3.13 (1H, m), 2.98-2.81 (2H, m), 2.63 (1H, dt, J = 13.6, 8.5 Hz), 2.29-2.21 and 2.16-2.09 (1H , m), 2.07-2.00 (1H, m), 1.73-1.33 (4H, m), 0.99 (3H, t, J = 7.4 Hz)
[173] Example 4
[174] [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[175] a) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol
[176] [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-chloro-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3- Step of Example 3 using Japanese] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol (prepared as described in WO 9703084) It was prepared according to the method of g). The crude product was purified (SiO ₂ , methanol: dichloromethane 1:19 as eluent) to give the subtitle compound.
[177] MS (APCI) 381 (M + H ⁺ , 100%)
[178] b) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylsulfonyl) -3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol
[179] Prepared according to the method of step f) of example 1 using the product of step a).
[180] MS (APCI) 413 (M + H ⁺ , 100%)
[181] c) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol
[182] 1-butanethiol (2.38 mL) in DMF (25 mL) was added to a suspension of sodium hydride (60%, 1.09 g) in DMF (50 mL). After 1 h, a solution of the product of step b) (3.66 g) in DMF (65 mL) was added dropwise and the resulting mixture was stirred overnight. The reaction mixture was slowly added to saturated aqueous sodium bicarbonate (1000 mL) and then extracted with ethyl acetate (3 × 200 mL). The organic phase was dried (MgSO ₄ ), concentrated in vacuo and the residue was purified (SiO ₂ , methanol: dichloromethane 1:19 as eluent) to give the title compound (3.32 g).
[183] MS (APCI) 395 (M + H ⁺ , 100%)
[184] d) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol acetate
[185] To a solution of the product of step c) (3.3 g) in dichloromethane (50 mL) was added pyridine (2.7 mL), 4-dimethylaminopyridine (0.4 g) and acetic anhydride (2.0 mL). The mixture was stirred at rt overnight, then concentrated in vacuo and purified (SiO ₂ , diethylether: isohexane 3: 2 as eluent) to give the title compound (2.7 g).
[186] MS (APCI) 437 (M + H ⁺ , 100%)
[187] e) [3aR- (3aα, 4α, 6α, 6aα)]-6- [7-bromo-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-methanol acetate
[188] Prepared according to the method of step i) of Example 3 using the product of step d).
[189] MS (APCI) 500/502 (M + H ⁺ ), 500 (100%)
[190] f) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol acetate
[191] Prepared according to the method of step j) of example 3 using the product of step d) of example 2 and the product of step e).
[192] MS (APCI) 589 (M + H ⁺ , 100%)
[193] g) [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol
[194] The product of step f) (0.64 g) in 80% aqueous acetic acid (30 mL) was heated at 80 ° C. for 1 h. The cooled mixture was poured into saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was dried and concentrated in vacuo to give a rubbery material which was dissolved in methanol (50 mL) / 10% aqueous potassium carbonate solution (3 mL). The solution was stirred for 30 minutes, neutralized with acetic acid and concentrated in vacuo. Purification (SiO ₂ , methanol: dichloromethane 1:19 as eluent) gave a solid, which was recrystallized (acetonitrile) to give the title compound (0.25 g).
[195] MS (APCI) 507 (M + H ⁺ , 100%)
[196] NMR δH (d ₆ -DMSO) 9.34 (1H, br), 7.40-7.23 (2H, m), 7.11-7.00 (1H, m), 5.06-4.93 (2H, m), 4.76-4.67 (2H, m) , 4.48-4.38 (1H, m), 3.91-3.84 (1H, m), 3.56-3.39 (2H, m), 3.21-3.08 (1H, m), 3.03-2.83 (2H, m), 2.32-2.17 ( 1H, m), 2.17-2.03 (2H, m), 1.91-1.77 (1H, m), 1.71-1.32 (4H, m), 1.32-1.17 (2H, m), 0.81 (3H, t)
[197] Example 5
[198] [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (4-fluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4,5-d] Pyrimidin-3-yl] -cyclopentane-1,2,3-triol
[199] a) [3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6- [7-[[(4-fluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[200] Prepared according to the method of step e) of example 1 using the product of step d) of example 1 and the product of step f) of example 3.
[201] MS (APCI) 501 (M + H ⁺ , 100%)
[202] b) [3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6-[[7-[(4-fluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo [4,5-d] pyrid Midin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[203] Prepared according to the method of step f) of example 1 using the product of step a).
[204] MS (APCI) 532 (M + H ⁺ , 100%)
[205] c) [3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6- [7-[[(4-fluorophenyl) cyclopropyl] amino] -5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[206] Prepared according to the method of step c) of Example 4 using the product of step b).
[207] MS (APCI) 515 (M + H ⁺ , 100%)
[208] [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (4-fluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4,5-d] Pyrimidin-3-yl] -cyclopentane-1,2,3-triol
[209] Prepared according to the method of step h) of example 1 using the product of step c).
[210] MS (APCI) 575 (M + H ⁺ , 100%)
[211] NMR δ H (d ₆ -DMSO) 7.26-7.22 (2H, m), 7.11 (2H, t), 4.99-4.90 (1H, m), 4.67-4.63 (1H, m), 3.93 (1H, s), 3.77 (1H, bs), 3.35-3.13 (1H, m), 3.00-2.80 (2H, m), 2.59-2.51 (1H, m), 2.15-2.11 (1H, m), 1.91-1.86 (1H, m) , 1.53-1.41 (3H, m), 1.35-1.30 (1H, m), 1.22 (2H, hexadecimal), 0.80 (3H, t)
[212] Example 6
[213] [1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[214] a) [1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo [ 4,5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[215] A subtitle compound was prepared according to the method of step f) of Example 1 using the product of step l) of Example 3.
[216] MS (APCI) 555 (M + H ⁺ , 100%)
[217] b) [1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[(3,3,3-trifluoropropyl) thio] -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[218] The title compound was prepared according to the method of step g) of Example 1 using the product of step a).
[219] MS (APCI) 555 (M + H ⁺ , 100%)
[220] NMR δH (d ₆ -DMSO) 9.45 (1H, d), 7.36-7.05 (3H, m), 5.05 (1H, d), 5.02 (1H, d), 4.95 (1H, m), 4.60 (2H, m ), 3.95 (1H, m), 3.86 (1H, m), 3.47 (4H, m), 3.30-3.11 (3H, m), 2.63-2.49 (3H, m), 2.19 (1H, m), 2.00 ( 1H, m), 1.53 (1H, m), 1.40 (1H, m)
[221] Example 7
[222] [1S- [1α, 2α, 3β, 5β (1S ^* , 2R ^* )]]-3- (2-hydroxyethoxy) -5- [7- (2-phenylcyclopropyl) amino] -5-[(3,3,3-trifluoropropyl) thio] -3H- 1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2-diol
[223] a) (1S-cis) -2-[[4-[[6-chloro-5-nitro-2-[(3,3,3-trifluoropropyl) thio] -4-pyrimidinyl] amino] -2-cyclopenten-l-yl] oxy] -acetic acid ethyl ester
[224] A solution of sodium azide (4.70 g) in degassed water (25 mL) was transferred to (1R, 4S) -4-hydroxy-2-cyclopenten-l-yl acetate (9.99 g) in tetrahydrofuran (60 mL). Was added to the solution and stirred for 10 minutes. Tetrakis (triphenylphosphine) palladium (O) (365 mg) was added and stirred for 10 minutes. The aqueous layer was separated and extracted twice with ethyl acetate. The combined organic layers were dried (MgSO ₄ ), concentrated and purified on a short column (SiO ₂ , ethyl acetate: isohexane 1: 2 as eluent) to give a yellow oil. This was dissolved in tetrahydrofuran (25 mL) and added slowly to a suspension of sodium hydride (2.94 g, 60% dispersion in oil) in tetrahydrofuran (60 mL) at -78 ° C. A solution of ethylbromoacetate (8.2 mL) in tetrahydrofuran (5 mL) was added and the mixture was warmed to 20 ° C. and stirred for 30 minutes. Aqueous ammonium chloride solution was added and the mixture was extracted with ether. The organic layer was dried (MgSO ₄ ), concentrated and purified (SiO ₂ , ether: isohexane 1: 5 as eluent) to give a colorless oil. A solution of this oil and triphenylphosphine (17.89 g) in tetrahydrofuran (90 mL) was stirred for 10 minutes. Water (15 mL) was added and the solution stirred for 18 hours. The solvent was removed in vacuo and the residue was azeotroduced with toluene and purified (SiO ₂ , ethyl acetate as eluent, then ethyl acetate-methanol-ammonia (90: 9: 1)) to give a pale yellow oil ( 7.14 g) was obtained.
[225] A solution of this compound in tetrahydrofuran (50 mL) was purified by 4,6-dichloro-5-nitro-2-[(3,3,3-trifluoropropyl) thio] pyridine in anhydrous tetrahydrofuran (100 mL). To a solution of midine (prepared as described in WO 9703084) (24.8 g) and N, N-diisopropylethylamine (77.5 mL) was added over 25 minutes and then stirred for 30 minutes. . Water was added and the mixture was extracted with ether (3 times). The organic layer was dried (MgSO ₄ ), concentrated and purified (SiO ₂ , ethyl acetate: isohexane 1: 4 as eluent) to give the title compound (7.39 g).
[226] MS (APCI) 367/9 (M- (EtO ₂ CCH ₂ O) ⁺ ), 367 (100%)
[227] b) (1S-cis) 2-[[4- [7-chloro-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5 -d] -pyrimidin-3-yl] -2-cyclopenten-l-yl] oxy] -acetic acid ethyl ester
[228] Prepared according to the method of steps e) and f) of Example 3 using the product of step a).
[229] MS (APCI) 348/50 (M− (EtO ₂ CCH ₂ O) ⁺ ), 348 (100%)
[230] c) [1S- (cis)] 2-[[4- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -2-cyclopenten-1-yl] oxy] -acetic acid ethyl ester
[231] Prepared according to the method of step g) of example 3 using the product of step b).
[232] MS (APCI) 433 (M + H ⁺ , 100%)
[233] d) [1S- (cis)] 2-[[4- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -2-cyclopenten-1-yl] oxy] -1-ethanol
[234] Prepared according to the method of step k) of example 3 using the product of step c).
[235] MS (APCI) 391 (M + H ⁺ , 100%)
[236] e) [3aR- (3aα, 4α, 6α, 6aα)]-2- [6- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2, 3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy] ethanol
[237] Product of step d) in acetone (5 mL) and water (1 mL) (454 mg), osmium tetroxide (0.1 M solution in t-butanol, 0.17 mL), N-methylmorpholine N-oxide (210 mg ) And pyridine (0.09 mL) were heated at 70 ° C. for 5 hours. Sodium hydrosulfite (330 mg) in water (1 mL) was added, the solvent was removed in vacuo and the residue was azeotrope with toluene. A solution of this product and p-toluenesulfonic acid (50 mg) in acetone (5 mL) and 2,2-dimethoxypropane (2 mL) was stirred for 3 hours. The solvent was removed in vacuo, an aqueous sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was dried (MgSO ₄ ), concentrated and purified (SiO ₂ , isohexane: acetone 5: 2 as eluent) to give the title compound (367 mg) as a white solid.
[238] MS (APCI) 465 (M + H ⁺ , 100%)
[239] f) [3aR- (3aα, 4α, 6α, 6aα)]-2- [6- [7-bromo-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2 , 3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy] ethanol
[240] Prepared according to the method of step i) of Example 3 using the product of step e).
[241] MS (APCI) 528/30 (M + H ⁺ ), 528 (100%)
[242] g) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6- (7-phenylcyclopropyl) amino] -5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [ 4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-1,3-dioxol-4-yloxy] ethanol
[243] Product of step f) and (1R-trans) -2-phenyl-cyclopropanamine, [R- (R ^* , R ^* )]-2,3-dihydroxybutanedioate (1: 1) Prepared as described in LA Mitscher et al., J. Med. Chem. 1986, 29, 2044), according to the method of step j) of Example 3.
[244] MS (APCI) 581 (M + H ⁺ , 100%)
[245] h) [1S- [1α, 2α, 3β, 5β (1S ^* , 2R ^* )]]-3- (2-hydroxyethoxy) -5- [7- (2-phenylcyclopropyl) amino] -5-[(3,3,3-trifluoropropyl) thio] -3H- 1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2-diol
[246] Prepared according to the method of step h) of example 1 using the product of step g).
[247] MS (APCI) 540 (M + H ⁺ , 100%)
[248] NMR δH (d ₆ -DMSO) 7.35-7.16 (5H, m), 4.97 (1H, q), 4.62-4.54 (1H, m), 3.98-3.92 (1H, m), 3.78-3.72 (1H, m) , 3.55-3.44 (4H, m), 3.26-3.19 (2H, m), 3.16-3.07 (1H, m), 2.70-2.61 (1H, m), 2.58-2.52 (1H, m), 2.23-2.18 ( 1H, m), 2.05-1.97 (1H, m), 1.86 (1H, s), 1.54-1.46 (1H, m), 1.38-1.30 (1H, m)
[249] Example 8
[250] [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -cyclopentane-1,2, -triol
[251] a) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6-[[7-[(3,4-difluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[252] A subtitle compound was prepared according to the method of step e) of example 1 using the product of step f) of example 3 and the product of step d) of example 2.
[253] MS (APCI) 519 (M + H ⁺ , 100%)
[254] b) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6-[[7-[(3,4-difluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo [4, 5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[255] A subtitle compound was prepared according to the method of Example f) of Example 1 using the product of step a).
[256] MS (APCI) 551 (M + H ⁺ , 100%)
[257] c) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4 , 5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol
[258] The subtitle compound was prepared according to the method of Example 4 step c) using the product of step b).
[259] MS (APCI) 533 (M + H ⁺ , 100%)
[260] d) [1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -cyclopentane-1,2,3-triol
[261] A subtitle compound was prepared according to the method of step h) of Example 1 using the product of step c).
[262] NMR δH (d ₆ -DMSO) 7.15-6.98 (3H, m), 6.67 (1H, s), 5.11-5.09 (1H, m), 4.82-4.76 (1H, m), 4.34-4.21 (3H, m) , 3.7 (1H, s), 3.2-2.92 (4H, m), 2.77 (1H, m), 2.42-2.36 (1H, m), 2.2-2.18 (1H, m), 1.42-1.25 (6H, m) , 0.9 (3H, q)
[263] MS (APCI) 493 (M + H ⁺ , 100%)
[264] Example 9
[265] [1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [5- (butylthio) -7-[(2-phenylcyclopropyl) amino] -3H-1,2,3-triazolo [4,5-d] pyrimidine-3 -Yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[266] a) [3aS- (3aα, 4α, 6α, 6aα)]-[tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] -carbamic acid Phenylmethyl ester
[267] Potassium carbonate (39.3 g) was added to [3aR- (3aα, 4α, 6α, 6aα)]-6-amino-tetrahydro-2,2-dimethyl-4H-cyclohexane in 4-methyl-2-pentanone (500 mL). Was added to a suspension of penta-1,3-diosol-4-ol hydrochloride (prepared as described in WO 9905142) (27.1 g). Then water (150 mL) was added followed by dropwise addition of benzylchloroformate (23.1 g). The reaction mixture was stirred at room temperature for 4 hours and then the organic phase was separated. The aqueous phase was extracted with 4-methyl-2-pentanone (2 x 50 mL). The organic phases were combined and concentrated and the residue was purified (SiO ₂ , dichloromethane: methanol 95: 5 to 90:10 as eluent) to give the subtitle compound (39.23 g).
[268] NMR δ H (CDCl ₃ ) 7.32 (5H, m), 5.65 (1H, br s), 5.10 (2H, br s), 4.59 (1H, d), 4.48 (1H, d), 4.27 (1H, m), 4.19 (1 H, br m), 2.24 (1 H, br s), 1.69 (1 H, d), 1.41 (3 H, s), 1.26 (3 H, s)
[269] b) [3aS- (3aα, 4α, 6α, 6aα)]-[2,2-dimethyl-6- (2-hydroxyethoxy) -tetrahydro-4H-cyclopenta-1,3-diosol-4 -Yl] -carbamic acid phenylmethyl ester
[270] Potassium t-butoxide (3.6 g) in tetrahydrofuran (20 mL) was added to a solution of the product of step a) (39.23 g) in tetrahydrofuran (200 mL) over 5 minutes. After 15 minutes, ethylbromoacetate (3.7 mL) in tetrahydrofuran (10 mL) was added dropwise. The mixture was stirred at 0 ° C. for 10 minutes, then additional ethyl bromoacetate was added (3.7 mL × 4). The reaction mixture was further stirred for 2 h at 0 ° C. Thereafter, lithium borohydride (2.79 g) was added little by little to the resulting suspension, and the reaction mixture was stirred at <5 ° C for 16 hours. Glacial acetic acid (23 g) was added dropwise to the cold mixture. After stirring for 30 minutes, water (100 mL) was added dropwise and the resulting mixture was stirred for 30 minutes. The phases are then separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases were washed with saturated sodium bicarbonate and brine, dried and concentrated. The residue was purified (SiO ₂ , ethyl acetate: hexane 25:75 to 50:50 as eluent) to give the title compound (38.6 g).
[271] MS (APCI) 218 (M + H ⁺ , 100%)
[272] c) [3aR- (3aα, 4α, 6α, 6aα)]-2-[[6-amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-diosol-4-yl] oxy ]-ethanol
[273] A slurry of 5% palladium on charcoal (4 g) in ethanol was added to a solution of the product of step b) (39.96 g) in ethanol (250 mL) and the mixture was hydrogenated at 1.2 bar for 20 hours. The catalyst was filtered off and the filtrate was concentrated to give the subtitle compound (23.65 g).
[274] MS (APCI) 160 (M + H ⁺ , 100%)
[275] d) 2- (butylthio) -4,6-dichloropyrimidin-5-amine
[276] A subtitle compound was prepared according to the method of step e) of Example 3 using 2- (butylthio) -4,6-dichloro-5-nitro-pyrimidine (prepared as described in DE 2223644).
[277] NMR δH (CDCl ₃ ) 4.20 (2H, br s), 3.10 (2H, t), 1.70 (2H, m), 1.47 (2H, m), 0.95 (3H, t)
[278] e) [3aR- (3aα, 4α, 6α, 6aα)]-2-[[6-[[5-amino-2- (butylthio) -6-chloro-pyrimidin-4-yl] amino] -tetra Hydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] ethanol
[279] Small title compounds were prepared according to the method of step d) of example 3 using the product of steps c) and d).
[280] MS (APCI) 433 (M + H ⁺ , 100%)
[281] f) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6-[[5- (butylthio) -7-chloro-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetra Hydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] ethanol
[282] The subtitle compound was prepared according to the method of step f) of Example 3 using the product of step e).
[283] NMR δH (CDCl ₃ ) 5.53 (1H, m), 5.21 (1H, m), 4.88 (1H, d), 4.05 (1H, m), 3.59 (4H, m), 3.24 (2H, t), 2.70 ( 1H, m), 2.53 (1H, m), 2.13 (1H, t), 1.79 (2H, m), 1.55 (5H, m), 1.37 (3H, s), 0.98 (3H, t)
[284] g) [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6-[[5- (butylthio) -7- [2-phenylcyclopropyl] amino-3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] -ethanol
[285] The subtitle compound was prepared according to the method of Example j) of Example 3 using the product of step f).
[286] MS (APCI) 541 (M + H ⁺ , 100%)
[287] h) [1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [5- (butylthio) -7-[(2-phenylcyclopropyl) amino] -3H-1,2,3-triazolo [4,5-d] pyrimidine-3 -Yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol
[288] The title compound was prepared according to the method of step h) of Example 1 using the product of step g).
[289] MS (APCI) 501 (M + H ⁺ , 100%)
[290] NMR δH (d ₆ -DMSO) 9.33 (1H, d), 7.30 (2H, m), 7.18 (3H, m), 5.12 (1H, d), 5.04 (1H, d), 4.96 (1H, q), 4.59 (2H, m), 3.94 (1H, s), 3.76 (1H, m), 3.51 (4H, m), 3.22 (1H, m), 2.98 (1H, m), 2.86 (1H, m), 2.65 (1H, m), 2.14 (1H, m), 2.05 (1H, m), 1.21-1.53 (6H, m), 0.80 (3H, t)
[291] Pharmacological Data
[292] Preparation for testing the P _2T (P2Y _ADP or P2T _AC ) receptor agonist / antagonist activity of the compounds of the invention in washed human platelets was performed as follows.
[293] Human venous blood (100 mL) was equally divided into three tubes each containing 3.2% trisodium citrate (4 mL) as an anticoagulant. The tube was centrifuged at 240 G for 15 minutes to obtain platelet rich plasma (PRP), to which 300 ng / ml prostacycline was added to stabilize platelets during the wash. PRP free of red blood cells was obtained by centrifugation at 125 G for 10 minutes, followed by further centrifugation at 640 G for 15 minutes. Discard supernatant and platelet pellets were modified calcium-free tie rod solution (10 mL) (CFT, composition: NaCl 137 mM, NaHCO ₃ 11.9 mM, NaH ₂ PO ₄ 0.4 mM, KCl 2.7 mM, MgCl ₂ 1.1 mM, Resuspend in 5.6 mM dextrose), gaseous with 95% O ₂ /5% CO ₂ and then maintain at 37 ° C. After addition of 300 ng / ml of PGI ₂ , the stored suspension was centrifuged once again at 640 G for 15 minutes. The supernatant was discarded and the platelets were first resuspended in 10 ml of CFT and additional CFT was added to adjust the final platelet count to 2 × 10 ⁵ / ml. The final suspension was stored in 60 ml syringe at 3 ° C. without air. Platelets were used in the aggregation test 2 hours after the final resuspension to allow recovery from normal functioning PGI ₂ -suppression.
[294] In all tests, a 3 ml aliquot of platelet suspension was added to a tube containing CaCl ₂ solution (60 μl of a 50 mM solution with a final concentration of 1 mM). Human fibrinogen (Sigma, F 4883) and 8-sulfophenyltheophylline (8-SPT used to block the P ₁ -agonist activity of the compound) were each at a final concentration of 0.2 mg / ml (10 of the coagulant protein in saline). 60 μl of mg / ml solution) and 300 nM (10 μl of 15 mM solution in 6% glucose) were added. If necessary, platelets or buffer was added to each well of a 96 well plate in a volume of 150 μl. All measurements were made three times for platelets from each donor.
[295] Agonist / antagonist effects were evaluated as follows.
[296] Aggregation in 96 well plates was measured using a change in absorbance presented by the plate reader at 660 nm. As a plate reader, a Bio-Tec Ceres 900C or Dynatech MRX was used.
[297] The absorbance of each well in the plate was read at 660 nm to establish a baseline. A suitable solution of saline or test compound was added to each well in a volume of 10 μl to a final concentration of 0, 0.01, 0.1, 1, 10 or 100 mM. The plate was then shaken for 5 minutes on an orbital shaker with a setting of 10 and the absorbance read at 660 nm. Aggregation at this point is indicative of the agonist activity of the test compound. Saline or ADP (30 mM; 450 mM 10 μl) was then added to each well and the plate was shaken for an additional 5 minutes before the absorbance was read again at 660 nm.
[298] Antagonist potency was estimated as% inhibition of control ADP response to determine IC ₅₀ . Exemplary compounds have a pIC ₅₀ value of at least 5.0.

权利要求:
Claims (21)
[1" claim-type="Currently amended] A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or solvate of such salt.
<Formula I>

In the above formula,
R ¹ is C _3-5 alkyl optionally substituted by one or more halogen atoms;
R ² is a phenyl group optionally substituted by one or more fluorine atoms;
R ³ and R ⁴ are both hydroxy;
R is XOH, where X is CH ₂ , OCH ₂ CH ₂ or a bond;
Provided that when X is CH ₂ or a bond, R ¹ is not propyl,
If X is CH ₂ and R ¹ is CH ₂ CH ₂ CF ₃ , butyl or pentyl, then the phenyl group in R ² should be replaced by fluorine,
If X is OCH ₂ CH ₂ and R ¹ is propyl, then the phenyl group in R ² must be replaced by fluorine.
[2" claim-type="Currently amended] The compound of claim 1, wherein R ¹ is 3,3,3-trifluoropropyl, butyl or propyl.
[3" claim-type="Currently amended] The compound of claim 1 or 2, wherein R ² is phenyl or 4-fluorophenyl or 3,4-difluorophenyl.
[4" claim-type="Currently amended] The compound of any one of claims 1-3, wherein R is CH ₂ OH or OCH ₂ CH ₂ OH.
[5" claim-type="Currently amended] The compound of claim 1, wherein [1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5 -[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl)- Cyclopentane-1,2-diol;
[1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[( 3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane- 1,2-diol;
[1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propyl Thio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol;
[1R- [1α, 2α, 3β (1R ^* , 2S ^* ), 5β]]-3- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (hydroxymethyl) -cyclopentane-1,2-diol;
[1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (4-fluorophenyl) cyclopropyl] amino]- 3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2,3-triol;
[1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[( 3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy)- Cyclopentane-1,2-diol;
[1S- [1α, 2α, 3β, 5β (1S ^* , 2R ^* )]]-3- (2-hydroxyethoxy) -5- [7- (2-phenylcyclopropyl) amino] -5- [ (3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -cyclopentane-1,2-diol;
[1S- [1α, 2β, 3β, 4α (1S ^* , 2R ^* )]]-4- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] cyclopentane-1,2,3-triol;
[1S- [1α, 2α, 3β (1S ^* , 2R ^* ), 5β]]-3- [5- (butylthio) -7-[(2-phenylcyclopropyl) amino] -3H-1,2, 3-triazolo [4,5-d] pyrimidin-3-yl] -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol; Or a pharmaceutically acceptable salt or solvate thereof or solvate of such salt.
[6" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 in combination with a pharmaceutically acceptable diluent, adjuvant and / or carrier.
[7" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischemic attack and / or peripheral vascular disease.
[8" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 for use in the treatment or prevention of unstable or stable angina.
[9" claim-type="Currently amended] A compound according to any one of claims 1 to 5 for use in therapy.
[10" claim-type="Currently amended] A compound according to any one of claims 1 to 5 for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischemic attack and / or peripheral vascular disease.
[11" claim-type="Currently amended] A compound according to any one of claims 1 to 5 for use in the treatment or prevention of unstable or stable angina.
[12" claim-type="Currently amended] Use of a compound according to any one of claims 1 to 5 as an active ingredient in the manufacture of a medicament for use in the treatment or prevention of myocardial infarction, thrombotic stroke, transient ischemic attack and / or peripheral vascular disease.
[13" claim-type="Currently amended] Use of a compound according to any one of claims 1 to 5 as an active ingredient in the manufacture of a medicament for use in the treatment or prevention of unstable or stable angina.
[14" claim-type="Currently amended] A method of treating or preventing platelet aggregation disorders, comprising administering to a person suffering from or susceptible to platelet aggregation disorders a therapeutically effective amount of a compound according to any one of claims 1 to 5.
[15" claim-type="Currently amended] A myocardial myocardium characterized by administering a therapeutically effective amount of a compound according to any one of claims 1 to 5 to a person suffering from or susceptible to myocardial infarction, thrombotic stroke, transient ischemic attack and / or peripheral vascular disease. A method of treating or preventing infarction, thrombotic stroke, transient ischemic attack and / or peripheral vascular disease.
[16" claim-type="Currently amended] A method of treating or preventing an unstable or stable angina, characterized by administering a therapeutically effective amount of a compound according to any one of claims 1 to 5 to a person suffering from or susceptible to such an unstable or stable angina.
[17" claim-type="Currently amended] Reacting a compound of formula (II) with a compound of formula (III) in an inert solvent in the presence of a base at ambient or elevated temperature, and then optionally converting one or more functional groups to additional functional groups, or removing a protecting group To form a pharmaceutically acceptable salt or solvate or solvate of such salts in any order.
<Formula II>

<Formula III>

In the above formula,
R, R ¹ , R ³ and R ⁴ are as defined in claim 1 or are protected derivatives thereof, or R ³ and R ⁴ together form a 5-membered ring or R is CH ₂ CH ₂ OR ' _Wherein R 'is C _1-6 alkyl or benzyl,
L is an exit group,
R ² is as defined in claim 1 or a protected derivative thereof.
[18" claim-type="Currently amended] [3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol ;
[[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (4-fluorophenyl) cyclopropyl] amino] -5-[(3, 3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl) -tetrahydro-2,2-dimethyl-4H-cyclopenta -1,3-dioxol-4-methanol;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5-[( 3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H- Cyclopenta-1,3-diosol-4-methanol;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3- Il] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;
[3aR- (3aα, 4α, 6α, 6aα)]-[[6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine- 3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol] oxy] acetic acid methyl ester;
[3aR- (3aα, 4α, 6α, 6aα)]-[[6- [7-bromo-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine -3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol] oxy] acetic acid methyl ester;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-[[6- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (Propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol -4-yl] oxy] acetic acid methyl ester;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6-[[7- [2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propyl Thio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4 -Yl] oxy] -ethanol;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3- Il] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (propylsulfonyl) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3 -Yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3- Il] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-amino-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3- Il] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol acetate;
[3aR- (3aα, 4α, 6α, 6aα)]-6- [7-bromo-5- (butylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidine-3 -Yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4-methanol acetate;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4 Methanol acetate;
[3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6- [7-[[(4-fluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H- 1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;
[3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6-[[7-[(4-fluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl) -3H -1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;
[3aR- [3aα, 4α, 6α, 6aα (1S ^* , 2R ^* )]]-6- [7-[[(4-fluorophenyl) cyclopropyl] amino] -5- (butylthio) -3H- 1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol;
[1S- (1α, 2α, 3β (1S ^* , 2R ^* ), 5β)]-3- [7-[[2- (3,4-difluorophenyl) cyclopropyl] amino] -5- (propyl Sulfonyl) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) -cyclopentane-1,2-diol;
(1S-cis) -2-[[4-[[6-chloro-5-nitro-2-[(3,3,3-trifluoropropyl) thio] -4-pyrimidinyl] amino] -2 -Cyclopenten-l-yl] oxy] -acetic acid ethyl ester;
(1S-cis) 2-[[4- [7-chloro-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5-d ] Pyrimidin-3-yl] -2-cyclopenten-1-yl] oxy] -acetic acid ethyl ester;
[1S- (cis)] 2-[[4- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -2-cyclopenten-1-yl] oxy] -acetic acid ethyl ester;
[1S- (cis)] 2-[[4- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3-triazolo [4,5 -d] pyrimidin-3-yl] -2-cyclopenten-1-yl] oxy] -1-ethanol;
[3aR- (3aα, 4α, 6α, 6aα)]-2- [6- [7-amino-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3- Triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy] ethanol;
[3aR- (3aα, 4α, 6α, 6aα)]-2- [6- [7-bromo-5-[(3,3,3-trifluoropropyl) thio] -3H-1,2,3 -Triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy] ethanol;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6- (7-phenylcyclopropyl) amino] -5-[(3,3,3-trifluoropropyl ) Thio] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-1,3-diosol-4-yljade Ci] ethanol;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6-[[7-[(3,4-difluorophenyl) cyclopropyl] amino] -5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-ol ;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6-[[7-[(3,4-difluorophenyl) cyclopropyl] amino] -5- (propylsulfonyl ) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-diosol-4- Come;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-6- [5- (butylthio) -7-[[2- (3,4-difluorophenyl) cyclopropyl] Amino] -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4 -Ol;
[3aS- (3aα, 4α, 6α, 6aα)]-[tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] -carbamic acid phenylmethyl ester;
[3aS- (3aα, 4α, 6α, 6aα)]-[2,2-dimethyl-6- (2-hydroxyethoxy) -tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl ] -Carbamic acid phenylmethyl ester;
[3aR- (3aα, 4α, 6α, 6aα)]-2-[[6-amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-diosol-4-yl] oxy]- ethanol;
2- (butylthio) -4,6-dichloropyrimidin-5-amine;
[3aR- (3aα, 4α, 6α, 6aα)]-2-[[6-[[5-amino-2- (butylthio) -6-chloro-pyrimidin-4-yl] amino] -tetrahydro- 2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] ethanol;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6-[[5- (butylthio) -7-chloro-3H-1,2,3-triazolo [ 4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] -ethanol;
[3aR- [3aα, 4α, 6α (1R ^* , 2S ^* ), 6aα]]-2- [6-[[5- (butylthio) -7- [2-phenylcyclopropyl] amino-3H-1, 2,3-triazolo [4,5-d] pyrimidin-3-yl] -tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl] oxy] -ethanol ;
[3aR- (3aα, 4α, 6α, 6aα)]-6-[[6-chloro-5-nitro-2- (propylthio) -pyrimidin-4-yl] amino] -tetrahydro-2,2- Dimethyl-4H-cyclopenta-1,3-dioxol-4-ol.
[19" claim-type="Currently amended] Compound of formula II.
<Formula II>

In the above formula,
R, R ¹ , R ³ and R ⁴ are as defined in claim 1 or are protected derivatives thereof, or R ³ and R ⁴ together form a 5-membered ring or R is CH ₂ CH ₂ OR ' _Wherein R 'is C _1-6 alkyl or benzyl,
L is an exit group.
[20" claim-type="Currently amended] Compound of Formula III:
<Formula III>

In the above formula,
R ² is as defined in claim 1 or a protected derivative thereof.
[21" claim-type="Currently amended] Compound of Formula V:
<Formula V>

In the above formula,
R ¹ is as defined in claim 1,
R is as defined in claim ₁ or a protected derivative thereof or OCH ₂ CO ₂ R 'wherein R' is C _1-6 alkyl or benzyl,
L is as defined above,
R ³ and R ⁴ are as defined in claim 1 or a protected derivative thereof, or R ³ and R ⁴ together form a bond in a 5-membered ring.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP2018021063A|2018-02-08|Syk inhibitors

---

US10428027B2|2019-10-01|Sulfinylphenyl or sulfonimidoylphenyl benzazepines

---

US9931343B2|2018-04-03|Deuterated baricitinib

---

EP3087077B1|2018-10-31|Inhibitors of the renal outer medullary potassium channel

---

JP5629324B2|2014-11-19|Pyrrolo [2,3-D] pyrimidine compounds

---

ES2404693T3|2013-05-28|Chemical procedure and intermediate compounds

---

FI106461B|2001-02-15|A process for the preparation of therapeutically useful enantiomeric compounds and a process useful intermediate

---

KR0145308B1|1998-07-15|Pyrimidines compound and pharmacologically active cns compounds

---

AU779065B2|2005-01-06|Pyrazolo | pyrimidine derivatives

---

CN1934091B|2012-02-08|imidazole compounds for the treatment of neurodegenerative disorders

---

TWI423803B|2014-01-21|Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives

---

EP1689751B1|2010-10-20|5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibiting activity

---

US6303604B1|2001-10-16|Pharmaceutical composition comprising 2,4-diamino-6-benzyloxy-s-triazine and inactivation of O6-alkylguanine-DNA-alkyltransferase

---

EA030115B1|2018-06-29|Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

---

US9062070B2|2015-06-23|Inhibitors of the renal outer medullary potassium channel

---

TWI381841B|2013-01-11|An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient

---

ES2295924T3|2008-04-16|Derivatives of tropane imidazopirine substituted with antagonist activity of ccr5 receptors for the treatment of hiv and inflammation.

---

US6958341B2|2005-10-25|Pyrazolopyrimidines as CRF antagonists

---

TW528755B|2003-04-21|2-|-tetrahydrofuran-3,4-diol derivatives

---

FI111722B|2003-09-15|Process for Preparation of the | Enantiomer of cis-4-amino-1- | - | -pyrimidin-2-one to be used as an antiviral agent

---

CA2926908A1|2015-06-04|Novel amino pyrimidine derivatives

---

US9249149B2|2016-02-02|Deuterated derivatives of ruxolitinib

---

US5206435A|1993-04-27|4-amino-2-cyclopentene-1-methanol

---

ES2225546T3|2005-03-16|Imidazopirimidine derivatives and triazolopirimidine derivatives.

---

CA2931329A1|2015-08-06|Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection

同族专利:

---

公开号 | 公开日

---

SI1386917T1|2011-09-30|

---

HU0105081A2|2002-05-29|

---

LU91819I2|2011-08-01|

---

PT1135391E|2004-07-30|

---

HK1061246A1|2009-06-05|

---

US20130109702A1|2013-05-02|

---

JP2008266345A|2008-11-06|

---

NO20012725D0|2001-06-01|

---

JP2007084551A|2007-04-05|

---

IL143232A|2008-12-29|

---

IL169013A|2015-10-29|

---

RU2007133926A|2009-03-20|

---

JP5043749B2|2012-10-10|

---

IL198040A|2015-06-30|

---

HU0105081A3|2004-11-29|

---

EP2322513A3|2011-08-24|

---

US7250419B2|2007-07-31|

---

IL143232D0|2002-04-21|

---

IL183969A|2011-03-31|

---

LU91819A9|

---

US20030144305A1|2003-07-31|

---

ES2216623T3|2004-10-16|

---

ES2318081T3|2009-05-01|

---

HU228589B1|2013-04-29|

---

CZ300373B6|2009-05-06|

---

AU2016500A|2000-06-26|

---

MY121867A|2006-02-28|

---

RU2317990C2|2008-02-27|

---

KR100776484B1|2007-11-28|

---

IL198040D0|2009-12-24|

---

EP1386909A1|2004-02-04|

---

CY1110501T1|2015-04-29|

---

TR200101567T2|2001-12-21|

---

AR023920A1|2002-09-04|

---

AR072756A2|2010-09-22|

---

JP4202607B2|2008-12-24|

---

CA2351709A1|2000-06-15|

---

US6974868B2|2005-12-13|

---

IL210398D0|2011-03-31|

---

PL201283B1|2009-03-31|

---

KR20060091056A|2006-08-17|

---

KR100822602B1|2008-04-16|

---

SA1506B1|2006-11-04|

---

US6525060B1|2003-02-25|

---

RU2012121883A|2013-11-27|

---

DE69915675T4|2012-08-30|

---

DK1386917T3|2011-08-29|

---

DE69915675D1|2004-04-22|

---

EP1135391A1|2001-09-26|

---

NO2011007I1|2011-06-06|

---

JP5415383B2|2014-02-12|

---

AT261970T|2004-04-15|

---

NO319806B1|2005-09-19|

---

KR100742924B1|2007-07-25|

---

EP1135391B1|2004-03-17|

---

AT418547T|2009-01-15|

---

DK1135391T3|2004-06-28|

---

DE69915675T2|2005-02-17|

---

IL183969D0|2009-02-11|

---

CN1128801C|2003-11-26|

---

HK1039933A1|2004-10-08|

---

NO20012725L|2001-07-31|

---

WO2000034283A1|2000-06-15|

---

PT1386921E|2009-02-23|

---

US20060025590A1|2006-02-02|

---

NO2011007I2|2012-07-09|

---

NZ511778A|2003-10-31|

---

US20150152111A1|2015-06-04|

---

TWI229674B|2005-03-21|

---

CN1334816A|2002-02-06|

---

EP2322513A2|2011-05-18|

---

SI1135391T1|2004-08-31|

---

SK286007B6|2008-01-07|

---

JP2002531567A|2002-09-24|

---

BR9915883A|2001-08-21|

---

EG24814A|2010-09-21|

---

EP1386921B1|2008-12-24|

---

CZ20011962A3|2001-11-14|

---

SI1386921T1|2009-04-30|

---

CA2351709C|2010-04-06|

---

HK1061684A1|2012-02-10|

---

EP1386917A1|2004-02-04|

---

SK7492001A3|2002-01-07|

---

US20130072503A1|2013-03-21|

---

US20140296258A1|2014-10-02|

---

CY1111759T1|2015-10-07|

---

EP1386921A1|2004-02-04|

---

BRPI9915883B1|2015-08-18|

---

EP1386917B1|2011-06-22|

---

US20100069408A1|2010-03-18|

---

US20120165348A1|2012-06-28|

---

US20080214812A1|2008-09-04|

---

ID29927A|2001-10-25|

---

DE69940171D1|2009-02-05|

---

KR20070007971A|2007-01-16|

---

DE122011100004I1|2011-09-08|

---

KR20070086540A|2007-08-27|

---

CZ300280B6|2009-04-08|

---

CZ295234B6|2005-06-15|

---

AT513816T|2011-07-15|

---

PL348724A1|2002-06-03|

---

AR058967A2|2008-03-05|

---

JP2011016831A|2011-01-27|

---

RU2593201C2|2016-08-10|

---

US20070265282A1|2007-11-15|

---

AU766618B2|2003-10-23|

---

DK1386921T3|2009-03-23|

---

KR100764417B1|2007-10-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1998-12-04|Priority to SE9804211-2

---

1998-12-04|Priority to SE9804211A

---

1999-04-09|Priority to SE9901271-8

---

1999-04-09|Priority to SE9901271A

---

1999-12-02|Application filed by 다비드 에 질레스, 아스트라제네카 아베

---

2001-08-25|Publication of KR20010081054A

---

2006-10-23|First worldwide family litigation filed

---

2007-07-25|Application granted

---

2007-07-25|Publication of KR100742924B1

优先权:

---

申请号 | 申请日 | 专利标题

---

SE9804211-2|1998-12-04|

---

SE9804211A|SE9804211D0|1998-12-04|1998-12-04|Novel compounds|

---

SE9901271-8|1999-04-09|

---

SE9901271A|SE9901271D0|1999-04-09|1999-04-09|Novel compounds|